跳至主要内容
临床试验/NCT00067444
NCT00067444已完成3 期

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed With Major Depressive Disorder

GlaxoSmithKline47 个研究点 分布在 1 个国家目标入组 560 人开始时间: 2003年6月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
560
试验地点
47
主要终点
Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score.

研究概览

简要总结

Major Depressive Disorder (MDD) Study in Elderly Outpatients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Major Depressive Disorder (MDD).
  • Current major depressive episode at screen at least 2 months duration.
  • Must be at least 60 years of age.

排除标准

  • Patients with a primary diagnosis other than MDD.
  • Patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder or dementia.
  • Patients with a history of brief depressive episodes lasting less than 8 weeks.
  • Patients receiving formal psychotherapy within 12 weeks of study.
  • Patients who are suicidal.
  • Patients who have received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening.
  • Patients with a history or seizure disorders.

结局指标

主要结局

Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score.

时间窗: 10 Weeks

次要结局

  • Mean change from baseline in HAM-D item 1; Mean change from baseline in the CGI severity of illness score at study endpoint; Percentage of patients with HAM-D total score less than or equal to 7.(10 Weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (47)

Loading locations...

相似试验

Depression Study In Elderly Patients | 临床试验